Lakeland Regional Medical Center

(863) 687-1100

Lakeland Regional Cancer Center
Lakeland Regional Cancer Center
Lakeland Regional Cancer Center

Print Page

Prostate Cancer

Clinical Trial #BN-301:

  • Vaccine therapy for men with rising PSA or new bone lesions or enlarging soft tissue mass following treatment with hormone therapy for prostate cancer.
  • Participants qualify if  between 18-85 years of age with a testosterone level less than 50.  PSA has to have risen at least two times or there is evidence of a new bone lesion.  Participants must have had a previous small pox vaccination.
  • Exclusions include, but are not limited to:  Prior Taxotere treatment, splenectomy or immunodeficiency, inflammatory eye disease, prior Provenge treatment, active skin disease, atopic dermatitis and an egg or Gentamycin allergy.

Clinical Trial # A031201:

  • Enzalutamide versus Enzalutamide & Abiraterone for patients with hormone resistant prostate cancer.
  • Patient’s progression can be rising PSAs, bone metastases or soft tissue disease advancement.
  • Exclusions include; but are not limited to: Prior chemotherapy for metastatic disease, seizures, brain metastases, unstable bone disease, hypotension, myocardial infarction within the last six months, gastrointestinal disorder or prior Enzalutamide or Abiraterone treatment.

 

Clinical Trial # S1216:

  • Androgen  deprivation with Casodex or TAK-700 for men with newly diagnosed metastatic, hormone sensitive disease.
  • Participants must have a PSA of 2 or greater and soft tissue AND/OR bone metastases.  Prior  neo-adjuvant or adjuvant treatment is allowed if it was greater than 2 years ago.  Prior palliative radiation is allowed.  Patients may currently be on bisphosphonates.
  • Exclusions include, but are not limited to: Brain metastases, uncontrolled hypertension, bilateral orchiectomy, adrenal insufficiency, HIV, HEP B and HEP C.

Clinical Trial #70807:

  • Participants must have a clinical stage of less than or equal to T2a  and  have chosen active surveillance.  This trial collects data with respects to dietary intervention versus unchanged diet.
  • Participants must be 50-80 years of age with less than 25% positive cores from biopsy.
  • Participants equal to or under the age of 70 are required to have a gleason score no higher than 6.
  • Participants over the age of 70 are required to have a gleason score no higher than 7.
  • Exclusions include, but are not limited to: prior radiation, surgery or androgen deprivation and must not be currently consuming six (6) or more fruits or vegetables daily.

 

 

 

© 2014 Lakeland Regional Medical Center